Sitting, nonambulatory SMA patients (biallelic SMN1 loss, three SMN2 copies, aged 6–<60 months) received a single dose of intrathecal onasemnogene abeparvovec. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.